Lung Cancer Clinical Trial
Official title:
A Phase I Study of Intensity Modulated Radiotherapy (IMRT) for Malignant Pleural Mesothelioma After Radical Pleurectomy/Decortication (PD)
The goal of this clinical research study is to find the highest tolerable dose of radiation that can be given to directly to the pleura (the outer lining of the lungs) using intensity modulated radiation therapy (IMRT) in patients with MM who have had a pleurectomy.
IMRT:
IMRT is a technique to deliver radiation that allows the radiation beam to be shaped around
the target area.
Radiation Dose Levels:
If you are found to be eligible to take part in this study, you will be assigned to receive
one of two doses of radiation therapy based on when you joined the study. If the first dose
is tolerated well by the first group of participants in this study, then the next group of
participants will receive the second, higher dose of radiation.
Practice Visit:
You will have a practice radiation visit about 6-14 weeks after your surgery. At this visit,
you will have a computed tomography (CT) scan that will be used by the study staff to target
where you will receive the IMRT.
A mold will also be made around your body and marks will be made on your skin to help
position your body correctly for the IMRT. This practice visit should take about 1-2 hours.
IMRT Visits:
Two (2) weeks after the practice radiation visit, you will begin receiving IMRT. At each
visit, you will lie down in the mold of your body that was made at the practice visit and you
will be lined up for the IMRT using the marks made at the practice visit. The IMRT will then
be delivered. You will receive IMRT every weekday (Monday-Friday) for up to 5 weeks. These
visits should last about 45-60 minutes.
Study Visits:
The following tests and procedures will be performed 1 time every week for up to 5 weeks
while you are on study:
- You will have a physical and skin exam.
- You will have lung function tests.
You will also have a chest x-ray and a four-dimensional (4D) CT scan to check the status of
the disease during the last week that you are receiving IMRT. A 4D CT scan is performed just
like a CT scan, but during the 4D CT scan, a small black box (about the size of a deck of
cards) will be placed on your abdomen. This box will allow more views of the tumor to be seen
during the scan by the study staff.
Length of Study:
You may receive IMRT for up to 5 weeks. The IMRT will be stopped early if the disease gets
worse or intolerable side effects occur.
Follow-up Visits:
One (1) month after your last dose of IMRT, you will have a chest x-ray, lung function tests,
4D CT scan and a physical exam. The chest x-ray and CT scan will be performed to check the
status of the disease.
Two (2) months after your last dose of IMRT, you will have a chest x-ray and a physical exam.
Three (3) months after your last dose of IMRT, you will have a chest x-ray, lung function
tests, a physical exam, a 4D CT scan and a regular CT scan of your chest. The chest x-ray and
CT scans will be performed to check the status of the disease.
Long-term Follow-up:
Every 3 months for 2 years, every 6 months for the next 3 years, and 1 time every year after
that, you will have lung function tests, a physical exam, and alternating CT and positron
emission tomography (PET) scans to check the status of the disease. This means that if you
have a CT scan at one visit, you will have a PET scan at the next visit, or vice versa.
This is an investigational study. IMRT given directly to the pleura in patients with MM after
a pleurectomy is currently being used for research purposes only.
Up to 22 patients will take part in this study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|